[go: up one dir, main page]

EP1594535A4 - Complexes de molecule antigene-proteine de phase aigue et proteines de fusion - Google Patents

Complexes de molecule antigene-proteine de phase aigue et proteines de fusion

Info

Publication number
EP1594535A4
EP1594535A4 EP04708276A EP04708276A EP1594535A4 EP 1594535 A4 EP1594535 A4 EP 1594535A4 EP 04708276 A EP04708276 A EP 04708276A EP 04708276 A EP04708276 A EP 04708276A EP 1594535 A4 EP1594535 A4 EP 1594535A4
Authority
EP
European Patent Office
Prior art keywords
fusion proteins
protein molecule
acute phase
molecule complexes
phase antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04708276A
Other languages
German (de)
English (en)
Other versions
EP1594535A2 (fr
Inventor
Pramod K Srivastava
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Connecticut Health Center
Original Assignee
University of Connecticut Health Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Connecticut Health Center filed Critical University of Connecticut Health Center
Publication of EP1594535A2 publication Critical patent/EP1594535A2/fr
Publication of EP1594535A4 publication Critical patent/EP1594535A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP04708276A 2003-02-04 2004-02-04 Complexes de molecule antigene-proteine de phase aigue et proteines de fusion Withdrawn EP1594535A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44476803P 2003-02-04 2003-02-04
US444768P 2003-02-04
PCT/US2004/003861 WO2004069204A2 (fr) 2003-02-04 2004-02-04 Complexes de molecule antigene-proteine de phase aigue et proteines de fusion

Publications (2)

Publication Number Publication Date
EP1594535A2 EP1594535A2 (fr) 2005-11-16
EP1594535A4 true EP1594535A4 (fr) 2006-07-12

Family

ID=32850927

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04708276A Withdrawn EP1594535A4 (fr) 2003-02-04 2004-02-04 Complexes de molecule antigene-proteine de phase aigue et proteines de fusion

Country Status (4)

Country Link
EP (1) EP1594535A4 (fr)
AU (1) AU2004208848A1 (fr)
CA (1) CA2515107A1 (fr)
WO (1) WO2004069204A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090269843A1 (en) * 2004-08-20 2009-10-29 Novo Nordisk A/S Hemopexin fusion proteins
EP2476440B1 (fr) * 2009-09-11 2017-08-02 Proyecto de Biomedicina Cima, S.L. Compositions thérapeutiques pour le traitement de maladies provoquées par le pvh

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001091787A1 (fr) * 2000-06-02 2001-12-06 University Of Connecticut Health Center Complexes d'alpha (2) macroglobuline et de molecules antigeniques a utiliser en immunotherapie

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001091787A1 (fr) * 2000-06-02 2001-12-06 University Of Connecticut Health Center Complexes d'alpha (2) macroglobuline et de molecules antigeniques a utiliser en immunotherapie

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BINDER R J ET AL: "Adjuvanticity of alpha 2-macroglobulin, an independent ligand for the heat shock protein receptor CD91", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 166, no. 8, April 2001 (2001-04-01), pages 4968 - 4972, XP002965476, ISSN: 0022-1767 *
BINDER R J ET AL: "Naturally formed or artificially reconstituted non-covalent alpha2-macroglobulin-peptide complexes elicit CD91-dependent cellular immunity", CANCER IMMUNITY, vol. 2, no. 16, 18 December 2002 (2002-12-18), pages 1 - 9,16, XP002965477, ISSN: 1424-9634 *
QIN ZEN ET AL: "Binding site on human C-reactive protein (CRP) recognized by the leukocyte CRP-receptor", JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 64, no. 1, 1997, pages 140 - 151, XP002369068, ISSN: 0730-2312 *
SUZUE K ET AL: "HEAT SHOCK FUSION PROTEINS AS VEHICLES FOR ANTIGEN DELIVERY INTO THE MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I PRESENTATION PATHWAY", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 94, November 1997 (1997-11-01), pages 13146 - 13151, XP002070395, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2004069204A3 (fr) 2004-11-25
WO2004069204A2 (fr) 2004-08-19
EP1594535A2 (fr) 2005-11-16
CA2515107A1 (fr) 2004-08-19
AU2004208848A1 (en) 2004-08-19

Similar Documents

Publication Publication Date Title
NO2017058I1 (no) HPV 58 L1 protein
NO2017012I1 (no) HPV 45 L1 protein
NO20071302L (no) Bindingdomene fusjonsproteiner
ATE480567T1 (de) Hochkonzentrierter antikörper und proteinformulierungen
EP1618181A4 (fr) Complexe proteinique polyvalent
LTC1641823I2 (lt) GLP-1 analogo sulieti baltymai
DK2236152T3 (da) Albuminfusionsproteiner
CY2014040I1 (el) Πρωτεϊνη συντηξης αλβουμινης
IS6881A (is) Samsett fjölgilt fjölsykru-próteinbóluefni gegn heilasóttarhnettlu
EP1359937A4 (fr) Ligands peptidiques modifies
DK1752470T3 (da) GAG-bindende proteiner
DK1653844T3 (da) Prionspecifikke peptidreagenser
DE60105696D1 (de) Eisenhaltige Proteinzusammensetzung
EP1735335A4 (fr) Peptide d'elimination cellulaire
NO20021275D0 (no) Transgent produserte fusjonsproteiner
EP1645563A4 (fr) Materiaux de repliement de proteine
IS8308A (is) Amínósýrur með sækni fyrir a2o prótíninu
EP1682572A4 (fr) Expression de proteines
EP1594535A4 (fr) Complexes de molecule antigene-proteine de phase aigue et proteines de fusion
EP1594534A4 (fr) Complexes de molecule antigene-proteine de phase aigue et proteines de fusion
EP1596882A4 (fr) Complexes de molecule antigene-proteine de phase aigue et proteines de fusion
EP1591451A4 (fr) Conjugue peptidique
EP1599223A4 (fr) Complexes de molecule antigene-ligand immunogene cd91 et proteines de fusion
EP1515991A4 (fr) Molecules signalisant la douleur
EP1466975A4 (fr) Proteines postsynaptiques

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050901

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/385 20060101ALI20060321BHEP

Ipc: A61K 39/00 20060101AFI20041206BHEP

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20060614

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060905